All News Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Real-time Estimate Cboe BZX Other stock markets 03:20:31 2024-04-25 pm EDT			5-day change	1st Jan Change
6.295 ^USD	-4.33%		-5.56%	-54.88%

Apr. 03	Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating	MT
Apr. 02	Sector Update: Health Care Stocks Slide Late Afternoon	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws	Apr. 19	PR
Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating	Apr. 03	MT
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 02	MT
Top Midday Decliners	Apr. 02	MT
Looming Factory Orders, Job Openings Data Prompt Lower Premarket Action for US Equity Futures	Apr. 02	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	Apr. 02	MT
Sector Update: Health Care	Apr. 02	MT
Verve Therapeutics Pauses Heart-1 Trial After Serious Adverse Events; Shares Fall Pre-Bell	Apr. 02	MT
Top Premarket Decliners	Apr. 02	MT
Verve Therapeutics Announces Updates on its PCSK9 Program	Apr. 02	GL
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels	Apr. 02	RE
Verve Therapeutics, Inc. Announces Updates on its PCSK9 Program	Apr. 02	CI
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	Mar. 28	GL
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	Mar. 01	GL
Verve Therapeutics Q4 Net Loss Widens, Collaboration Revenue Rises; Beats Estimates; Shares Rise	Feb. 27	MT
Verve Therapeutics: Q4 Earnings Snapshot	Feb. 27	AQ
Verve Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 27	GL
Verve Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 01	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

All News

Filters